BT-7480 by Bicycle Therapeutics for Gastric Cancer: Likelihood of Approval

BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Gastric Cancer.

Florida car dealer joins insulin pricing fight against Eli Lilly, Sanofi

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 4, 2025

New compound HPH-15 offers promising alternative to diabetes medications

Kumamoto University scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marking a significant leap

December 6, 2024

Novartis snaps up rare disease biotech DTx Pharma in $1bn deal –

DTx Pharma’s Charcot-Marie-Tooth therapy candidate was able to induce remyelination of axons. Axons in patients with type 1 of the disease have myelin abnormalities. Image

July 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.